JPS60239417A - Preparation of freeze-dried emulsion drug - Google Patents

Preparation of freeze-dried emulsion drug

Info

Publication number
JPS60239417A
JPS60239417A JP9691084A JP9691084A JPS60239417A JP S60239417 A JPS60239417 A JP S60239417A JP 9691084 A JP9691084 A JP 9691084A JP 9691084 A JP9691084 A JP 9691084A JP S60239417 A JPS60239417 A JP S60239417A
Authority
JP
Japan
Prior art keywords
freeze
emulsion
oil
dried
aqueous phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9691084A
Other languages
Japanese (ja)
Inventor
Tsunenori Suyama
巣山 恒典
Junichi Okada
純一 岡田
Shogo Ueda
上田 省吾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Priority to JP9691084A priority Critical patent/JPS60239417A/en
Publication of JPS60239417A publication Critical patent/JPS60239417A/en
Pending legal-status Critical Current

Links

Abstract

PURPOSE:To obtain the titled drug consisting of an easily soluble freeze-dried cake and containing redispersed oil droplets having sufficiently small size to enable the administration by intravenous injection, by dissolving a vehicle and a specific water-soluble polymer in the aqueous phase of an O/W-type emulsion, and freeze-drying the solution. CONSTITUTION:A vehicle (e.g. saccharide, urea, etc.) and a water-soluble polymer selected from PVA, polyvinyl pyrrolidone, low-molecular weight gelatin, PEG, etc. are dissolved in the aqueous phase of an O/W-type emulsion. The obtained aqueous solution is mixed with an oil (e.g. soybean oil, linoleic acid, etc.) preferably at a ratio of (30-15):1, emulsified, and freeze-dried to obtain the objective drug preparation. The dissolution of the water-soluble polymer in the aqueous phase is effective to prevent the coagulation of the emulsion particles in the freeze-drying process, and accordingly, the obtained cake has excellent appearance and solubility and gives an emulsion having oil particle diameter of <=2-3mum.

Description

【発明の詳細な説明】 本発明は、再溶解する場合に容易に浴解し、かつ油滴直
径が数μm以下になるエマルションが再現できる製剤の
製法に関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a method for producing a preparation that is easily dissolved in a bath when redissolved and can reproduce an emulsion in which the diameter of oil droplets is several μm or less.

またエマルション油滴はリンパ指向性や薬物の貯蔵庫と
しての持続的放出性などの特徴を持つことなども知られ
ている。この特徴を利用すれば、制癌剤を始めとしいか
なる油溶性薬物でもそれを油滴中に溶解含有したO/W
エマルションを調製し有効な製剤にすることが可能であ
る。
It is also known that emulsion oil droplets have characteristics such as lymphatic tropism and sustained release properties as drug storage. Utilizing this feature, any oil-soluble drug, including anticancer drugs, can be dissolved in O/W containing it in oil droplets.
Emulsions can be prepared into effective formulations.

このように特に近年O/W型エマルションの医薬品分野
に於ける重要性が高まっている。ところがO/W型エマ
ルションはそれ自身の物理的安定性が悪いこと、また油
滴中に含有される主薬の化学的安定性が悪いこと、更に
は凍結が起こるとエマルション構造か破壊するというよ
うな欠点を有する。従って加水再溶解することによって
十分微細なエマルションが再現できる製剤が調製できれ
ば上記の欠点を改善できると期待される。このような観
点から水相中に表皮形成剤を溶解したエマルションを凍
結乾燥することによって復元時にエマルションになり易
い粉末製品が知られている (%開111852−12
5615号)。
As described above, the importance of O/W type emulsions in the pharmaceutical field has particularly increased in recent years. However, O/W emulsions themselves have poor physical stability, the chemical stability of the active ingredient contained in the oil droplets is poor, and furthermore, the emulsion structure may be destroyed when freezing occurs. It has its drawbacks. Therefore, it is expected that the above-mentioned drawbacks can be improved if a preparation that can reproduce a sufficiently fine emulsion by redissolving with water can be prepared. From this point of view, a powder product is known that easily becomes an emulsion upon reconstitution by freeze-drying an emulsion in which a skin-forming agent is dissolved in an aqueous phase (%Open 111852-12
No. 5615).

しかし、この方法でall製された製品を再乳化したエ
マルションは、その粒径が最大500 pmとかなり大
きいこと、更に再乳化するときの溶解性が必ずしも良好
ではないという欠点を有する。
However, the emulsion obtained by re-emulsifying all products manufactured by this method has the disadvantage that its particle size is quite large, up to 500 pm, and furthermore, the solubility during re-emulsification is not necessarily good.

すなiち、注射用エマルションの粒径は通例7μm以下
にするべきとされており(日本薬局方参照)、特に静脈
内注入用の場合大きな油滴は血管を塞栓するという重大
な危険性を持っている。
In other words, the particle size of emulsions for injection should generally be 7 μm or less (see Japanese Pharmacopoeia), and large oil droplets pose a serious risk of embolizing blood vessels, especially when used for intravenous injection. have.

従って従来知られている方法で調製したエマルション凍
結乾燥製剤は静脈用には使えないなど用途が限られる。
Therefore, emulsion freeze-dried preparations prepared by conventionally known methods have limited applications, such as being unable to be used intravenously.

そこで本発明者らはエマルション凍結乾燥製剤について
種々研究した結果、凍結乾燥ケーキが溶解し易く、かつ
再分散油滴が静脈内投与に使用できる程度に微小になる
製剤の製法を見出し本発明を完成した。
As a result of various studies on freeze-dried emulsion preparations, the present inventors discovered a method for producing a preparation in which the freeze-dried cake dissolves easily and the redispersed oil droplets are small enough to be used for intravenous administration, and have completed the present invention. did.

本発明の%徴は乾燥ケーキを形成する賦形剤および凍結
乾燥工程におけるエマルション粒子の凝集合一を防止す
る為に特定の水溶性高分子ヲエマルション水相に溶解し
て凍結乾燥する点にある。この結果、賦形剤および特定
の水溶性高分子によってケーキの外観・溶解性が良好に
なり、しかも微小な油滴が再分散できるような凍結乾燥
品を得ることができる。
The feature of the present invention is that a specific water-soluble polymer is dissolved in the aqueous phase of the emulsion and then freeze-dried to prevent excipients forming a dry cake and agglomeration of emulsion particles during the freeze-drying process. . As a result, it is possible to obtain a freeze-dried product in which the appearance and solubility of the cake are improved by the excipient and the specific water-soluble polymer, and in which fine oil droplets can be redispersed.

次に、本JIIJの製法について述べる。エマルション
の連続相となる水相には予じめ賦形剤と水溶性高分子を
溶解する。使用される賦形剤としては、人体に投与可能
で、また凍結乾燥の行ない易い物性を有する賦形剤であ
れば特に限定はない。そのような賦形剤としては糖類(
マン適な例として挙げられる。これらの賦形剤を5〜4
0 w/wチ、好ましくは18〜20 w/wチの濃度
で水溶液にする。このようにして得られた賦形剤水溶液
に更に水溶性高分子としてポリビニルアルコール(分子
Ji 300〜3000 )、ポリビニルピロリドン(
分子量10000〜1200000)、低分子量ゼラチ
ン(分子量5000〜20000 ) 、ハイドロキシ
プロビルセルロース(分子!20000〜100000
 ) 、ポリエチレングリコール(分子量4000〜2
0000 )、デキストラン(分子H1ooo。
Next, the manufacturing method of this JIIJ will be described. Excipients and water-soluble polymers are dissolved in advance in the aqueous phase, which is the continuous phase of the emulsion. The excipient used is not particularly limited as long as it can be administered to the human body and has physical properties that facilitate freeze-drying. Such excipients include sugars (
This is a good example. 5 to 4 of these excipients
It is made into an aqueous solution at a concentration of 0 w/w, preferably 18-20 w/w. The excipient aqueous solution thus obtained is further added to the water-soluble polymers such as polyvinyl alcohol (molecular Ji 300 to 3000), polyvinylpyrrolidone (
molecular weight 10000-1200000), low molecular weight gelatin (molecular weight 5000-20000), hydroxyprobyl cellulose (molecular weight 20000-100000)
), polyethylene glycol (molecular weight 4000-2
0000), dextran (molecule H1ooo.

〜100000 ) 、メトキシエチレン無水マレイン
酸共重合体(分子量200000〜150000G )
またはシクロデキストリン(分子i1972〜1zsy
 )から選ばれた一種を0.5〜SW/Wチ、好ましく
は1.2〜2.5 W/V%の濃度で溶解する。
~100000), methoxyethylene maleic anhydride copolymer (molecular weight 200000~150000G)
or cyclodextrin (molecule i1972~1zsy
) is dissolved at a concentration of 0.5 to SW/W%, preferably 1.2 to 2.5 W/V%.

このようにして得られた水溶液を油と50:1〜10 
: 1、好ましくは30:1〜15:1に混合し乳化す
る。使用される油は注射可能な油であれば特に限定はな
く、例えば植物性油(大豆油、ゴマ油、オリーブ油、ヤ
シ油など)、植物性脂肪酸(リノール酸、オレイン酸な
ど)などが挙げられる。油には予じめ薬物を溶解してお
く。薬物はその油に溶解するもので水に難溶のものであ
れば種類を選ばず、その例としては制御剤、抗生物質、
抗炎症剤、抗ヒスタミン剤、消化性fk傷治療剤、ビタ
ミン剤などが挙げられる。
The aqueous solution thus obtained was mixed with oil at a ratio of 50:1-10.
: 1, preferably 30:1 to 15:1 and emulsified. The oil used is not particularly limited as long as it is an injectable oil, and examples thereof include vegetable oils (soybean oil, sesame oil, olive oil, coconut oil, etc.), vegetable fatty acids (linoleic acid, oleic acid, etc.), and the like. Dissolve the drug in oil in advance. Drugs can be of any type as long as they are soluble in oil and poorly soluble in water; examples include control agents, antibiotics,
Examples include anti-inflammatory agents, antihistamines, agents for treating peptic fk wounds, and vitamin preparations.

乳化剤である界面活性剤はO/W型エマルションをfA
#するのに適した、親水性のものであれば特に種類を選
はない。そのような乳化剤としては、例えばホリオキシ
エチレンソルビタン脂肪酸エステル、ポリオキシエチレ
ン脂肪酸エステル、ポリオキシヒマシ油誘導体、ポリオ
キシエチレン高級アルコール、ポリオキシエチレン2ノ
リン誘導体、ホリオキシプロピレンポリオキシエテレン
アルキルエーテル、ポリオキシエチレンアルキルフェニ
ールエーテル、レシチンなどが挙げられる。
Surfactants, which are emulsifiers, make O/W emulsions fA.
There is no particular choice as to the type as long as it is hydrophilic and suitable for #. Examples of such emulsifiers include holoxyethylene sorbitan fatty acid ester, polyoxyethylene fatty acid ester, polyoxycastor oil derivative, polyoxyethylene higher alcohol, polyoxyethylene di-noline derivative, holoxypropylene polyoxyethylene alkyl ether, Examples include polyoxyethylene alkyl phenyl ether and lecithin.

乳化は、エマルション中の油滴直径が1μm以下になる
程度に行なう。これを凍結乾燥用容器に小分し通常の凍
結乾燥プログラムで凍結乾燥する。通常のプログラムと
は、賦形剤だけの水溶液を凍結乾燥することのできるプ
ログラムでおる。
Emulsification is carried out to such an extent that the diameter of oil droplets in the emulsion is 1 μm or less. This is aliquoted into freeze-drying containers and freeze-dried using a normal freeze-drying program. A normal program is a program that can freeze-dry an aqueous solution containing only excipients.

完成した凍結乾燥ケーキの外観は良好であり、凍結前に
小分した液量とf′!1.ゾ同量の水を加えて軽く振り
混ぜると速やかに溶解しエマルショントナル。このエマ
ルション中の油滴の直径は2〜3μm以下である。
The appearance of the completed freeze-dried cake was good, and the amount of liquid that was subdivided before freezing and f'! 1. When you add the same amount of water and mix gently, it dissolves quickly and becomes an emulsion toner. The diameter of the oil droplets in this emulsion is less than 2-3 μm.

以下に実施例を挙げて本発明を更に詳しく説明する。The present invention will be explained in more detail with reference to Examples below.

実施例1゜ 表1に示す処方を混和し、マントンゴーリン乳化機を用
い約soO#/dの圧力で乳化を行なった。エマルショ
ン粒径は1μm以下であった。
Example 1 The formulations shown in Table 1 were mixed and emulsified using a Manton-Gorlin emulsifier at a pressure of about soO#/d. The emulsion particle size was 1 μm or less.

このエマルションをバイアル瓶に2−ずつ小分(液厚的
70)した。これを−40℃から+30℃まで約15時
間で昇温するプログラムで凍結乾燥(真空度= 0.0
2 torr ) l、たとこる良好な凍結乾燥ケーキ
が得られた。これに2ゴの水を加え軽く振り混ぜると癒
やかに溶解し、エマルション粒径は2〜3μm以下で均
一であった。
This emulsion was divided into 2 portions (liquid thickness 70) into vials. This was freeze-dried using a program that raised the temperature from -40℃ to +30℃ in about 15 hours (degree of vacuum = 0.0
A freeze-dried cake with a good quality of 2 torr) was obtained. When two tablespoons of water were added to this and the mixture was gently shaken, it was dissolved gently, and the emulsion particle size was uniform at 2 to 3 μm or less.

実施例λ 実施例1において、リノール酸の中に制癌剤ACNUを
2v予じめ溶解しておき、その他は同様の操作を行なっ
た。その結果、油滴中にACNUを含む、実施例1と同
様の結果の製品が得られた。
Example λ In Example 1, 2 vol of the anticancer drug ACNU was dissolved in advance in linoleic acid, and the other operations were the same. As a result, a product containing ACNU in the oil droplets and having the same results as in Example 1 was obtained.

実施例3゜ 実施例1においてリノール酸の中にビタミンAを0.1
を予じめ混合しておき、その他は同様の操作を行なった
。その結果油滴中にビタミンAを含む、実施例1と同様
の結果の製品が得られた。
Example 3゜In Example 1, 0.1% vitamin A was added to linoleic acid.
were mixed in advance, and the other operations were the same. As a result, a product containing vitamin A in the oil droplets and having the same results as in Example 1 was obtained.

実施例4゜ 表2に示す11[1]の処方について実施例1と同様の
操作を行なった。製品の外ml、品質ともに実施例1と
同様であった。
Example 4 The same operation as in Example 1 was carried out for the formulation 11 [1] shown in Table 2. The external ml and quality of the product were the same as in Example 1.

本ジオクチルドデシルトリグリセライド(ヤシ油から分
溜したもの)参考例1゜ 実施例1における表1の処方の中で低分子量ゼラチンを
カルボキシメチルセルロースナトリウムに代えて同様の
操作を行なった。凍結乾燥ケーキの外観、溶解性ともに
良好であるが再分散したエマルションの油滴は分散性が
不良で凝集が撤しかった。
Dioctyldodecyl triglyceride (fractionated from coconut oil) Reference Example 1 The same procedure as in Example 1 was carried out except that the low molecular weight gelatin was replaced with sodium carboxymethylcellulose in the formulation shown in Table 1. Although the appearance and solubility of the freeze-dried cake were good, the oil droplets of the redispersed emulsion had poor dispersibility and were unable to agglomerate.

参考例λ 実施例1の低分子量ゼラチンをアラビアゴムに代えて同
様の操作を行なった。凍結乾燥ケーキの外観、溶解性と
もに良好であるがエマルション油滴は粒径的10〜20
1tmの大きなものが混在した。
Reference Example λ The same operation as in Example 1 was carried out except that the low molecular weight gelatin was replaced with gum arabic. The appearance and solubility of the freeze-dried cake are good, but the emulsion oil droplets have a particle size of 10 to 20.
Large ones of 1tm were mixed in.

参考例3゜ 実施例1の低分子量ゼラチンをゼラチン(分子量約40
000 )に代えて同様の操作を行なった。
Reference Example 3゜The low molecular weight gelatin of Example 1 was replaced with gelatin (molecular weight approximately 40
000) and the same operation was performed.

凍結乾燥ケーキの外観は良好であり、また再分散エマル
ションの粒子径も2〜3μm以下であるが、溶解性が不
良であった。
Although the appearance of the freeze-dried cake was good and the particle size of the redispersed emulsion was 2 to 3 μm or less, the solubility was poor.

Claims (1)

【特許請求の範囲】[Claims] エマルション凍結乾燥製剤の製法において、0 /W型
エマルションの水相中に賦形剤およびポリビニルアルコ
ール、ポリビニルピロリドン、低分子量ゼラチン、ハイ
ドロキシプロピルセルロース、ホリエテレングリコール
、デキストラン、メトキシエチレン、無水マレイン酸共
重合体またはシクロデキストリンから選ばれた水溶性両
分子の一種を溶解することを特徴とする凍結乾燥製剤の
製法。
In the method for producing emulsion freeze-dried preparations, excipients and polyvinyl alcohol, polyvinylpyrrolidone, low molecular weight gelatin, hydroxypropyl cellulose, polyethylene glycol, dextran, methoxyethylene, maleic anhydride copolymer are added to the aqueous phase of the 0/W emulsion. A method for producing a freeze-dried preparation, characterized by combining or dissolving two types of water-soluble molecules selected from cyclodextrins.
JP9691084A 1984-05-15 1984-05-15 Preparation of freeze-dried emulsion drug Pending JPS60239417A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP9691084A JPS60239417A (en) 1984-05-15 1984-05-15 Preparation of freeze-dried emulsion drug

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9691084A JPS60239417A (en) 1984-05-15 1984-05-15 Preparation of freeze-dried emulsion drug

Publications (1)

Publication Number Publication Date
JPS60239417A true JPS60239417A (en) 1985-11-28

Family

ID=14177513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9691084A Pending JPS60239417A (en) 1984-05-15 1984-05-15 Preparation of freeze-dried emulsion drug

Country Status (1)

Country Link
JP (1) JPS60239417A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034623A1 (en) * 1997-02-05 1998-08-13 Kirin Beer Kabushiki Kaisha Freeze-dried composition containing glycosphingolipid and process for producing the same
US5882684A (en) * 1992-12-24 1999-03-16 Schwarz Pharma Ag Lyophilized emulsion containing an active substance
US6417167B1 (en) 1997-02-05 2002-07-09 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing shingoglycolipid and process for preparing them
US7153572B2 (en) 2002-07-30 2006-12-26 Conopco, Inc. Porous beads and method of production thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52125615A (en) * 1976-04-09 1977-10-21 Kyowa Hakko Kogyo Co Ltd Method of making powdered products
JPS5449317A (en) * 1977-08-05 1979-04-18 Battelle Memorial Institute Dehydrating of liposome colloidal dispersion
JPS60224617A (en) * 1984-03-30 1985-11-09 ソシエテ、アノニム、デイツト:ラボラトアール、エル、ラフオン Medicine for oral administration and preparation of same by freeze drying oil-in-water emulsion

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52125615A (en) * 1976-04-09 1977-10-21 Kyowa Hakko Kogyo Co Ltd Method of making powdered products
JPS5449317A (en) * 1977-08-05 1979-04-18 Battelle Memorial Institute Dehydrating of liposome colloidal dispersion
JPS60224617A (en) * 1984-03-30 1985-11-09 ソシエテ、アノニム、デイツト:ラボラトアール、エル、ラフオン Medicine for oral administration and preparation of same by freeze drying oil-in-water emulsion

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882684A (en) * 1992-12-24 1999-03-16 Schwarz Pharma Ag Lyophilized emulsion containing an active substance
WO1998034623A1 (en) * 1997-02-05 1998-08-13 Kirin Beer Kabushiki Kaisha Freeze-dried composition containing glycosphingolipid and process for producing the same
US6417167B1 (en) 1997-02-05 2002-07-09 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing shingoglycolipid and process for preparing them
US7153572B2 (en) 2002-07-30 2006-12-26 Conopco, Inc. Porous beads and method of production thereof

Similar Documents

Publication Publication Date Title
Maja et al. Sustainable technologies for liposome preparation
EP0102265B1 (en) Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4542025A (en) Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
Dumortier et al. A review of poloxamer 407 pharmaceutical and pharmacological characteristics
CA1233119A (en) Method for preparing a galenic form for oral administration by lyophilization of an oil-in-water emulsion
ES2283394T3 (en) IMPLEMENTATION KIT CONTAINING A SUPPORT PHASE AND A SOLVENT.
JPS63240936A (en) Manufacturing method of dispersed colloid system of ultrafine particulate matter
JPH0657005A (en) Continuous production of nanocapsule or nanoparticle dispersion colloidal system
WO2003103596A2 (en) Stabilized nanoparticle formulations of camptotheca derivatives
KR0154343B1 (en) Lyophilized fatty emulsions and a process for the production thereof
JP4073478B2 (en) Biodegradable controlled-release microspheres and their production
JP6770754B2 (en) An improved preparation of levosimendan as an infusion or injection and for intravenous administration of infusion concentrates
CN101186706B (en) Preparation method for PEG series gel nano particles
CN1197388A (en) Pharmaceutical compsn. for oral delivery
JPS62270521A (en) Flurbiprofen preparation for ophthalmic administration
CA2495899A1 (en) Solid nano pharmaceutical formulation and preparation method thereof
Ofokansi et al. Formulation and evaluation of microspheres based on gelatin-mucin admixtures for the rectal delivery of cefuroxime sodium
EP3821920A1 (en) Combination for endoscopic surgery
KR100211772B1 (en) Lyophilized emulsion containing an active substance
WO2018196819A1 (en) Protein particle wrapped with medicine insoluble in water and preparation method therefor
KR101342119B1 (en) Method for preparing nano-scale particle of active material using diol compound
JPS60239417A (en) Preparation of freeze-dried emulsion drug
JP2758297B2 (en) Liposome preparation
CN113786393A (en) Rivaroxaban microsphere and preparation method and application thereof
JPH0543450A (en) Lyophilized preparation